Proof of concept for antibody-mediated delivery of sTNF has been generated for stromal (FAP), endothelial (integrins), and cellular targets (e.g., EGFR and Her2) (reviewed in [25]), with very favorable tumor-to-blood ratios 2-3 days after injection and potent tumoricidal activity at doses below the Maximum Tolerated Dose (MTD) of sTNF in preclinical models [26–28]. This evidence concerns the gene FAP and neoplasm.